Abstract:Identification of immunogenic targets against hepatitis B virus (HBV)-encoded proteins will provide crucial advances in developing potential antibody therapies. In this study, 63 treatment-naive patients with chronic HBV infection and 46 patients who achieved hepatitis B surface antigen loss (sAg loss) following antiviral treatment were recruited. Moreover, six patients who transitioned from the hepatitis B e antigen-positive chronic infection phase (eAg(+)CInf) to the hepatitis phase (eAg(+)CHep) were enrolled from real-life clinical practice. Additionally, telbivudine-treated eAg(+)CHep patients and relapsers or responders from an off-treatment cohort were longitudinally studied. The frequencies and function of B cells were assessed by flow cytometry. We devised a peptide array composed of 15-mer overlapping peptides of HBV-encoded surface (S), core (C), and polymerase (P) proteins and performed a screening on B-cell linear epitopes with sera. Naive B cells and plasmablasts were increased, whereas total memory, activated memory (AM), and atypical memory (AtM) B cells were reduced in sAg(-) patients compared with sAg(+) patients. Importantly, longitudinal observations found that AtM B cells were associated with successful treatment withdrawal. Interestingly, we identified six S-specific dominant epitopes (S33, S34, S45, S76, S78, and S89) and one C-specific dominant epitope (C37) that reacted with the majority of sera from sAg(-) patients. Of note, more B-cell linear epitopes were detected in CHep patients with alanine aminotransferase (ALT) flares than in nonflare CInf patients, and five B-cell linear epitopes (S4, S5, S10, S11, and S68) were overwhelmingly recognized by ALT flare patients. The recognition rates of epitopes on C and P proteins were significantly increased in CHep patients relative to CInf patients. Strikingly, a statistically significant elevation in the number of positive epitopes was observed when ALT nonflare patients shifted into the flare phase. Moreover, S76 identified at baseline was confirmed to be associated with a complete response after 48 weeks of telbivudine therapy. Taken together, we identified several functional cure-related B-cell linear epitopes of chronic HBV infection, and these epitopes may serve as vaccine candidates to elicit neutralizing antibodies to treat HBV infection.

Preparation and identification of HBc-HLA-A~* 1101-β_2m complex monomer and tetramer

Construction of HLA-A2-peptide tetramer and application in HBV/HCV infection]

Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.

Identification of the Association Between HBcAg-specific T Cell and Viral Control in Chronic HBV Infection Using a Cultured ELISPOT Assay.

[Detection of HBV Specific Cytotoxic Lymphocytes Responses in Severe Hepatitis B Patients Using MHC-peptide Tetramer Flow Cytometry].

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

In-vitro refolding and biotinylation of soluble HLA-A2-peptide complex]

Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes.

Determination of circulating HBV specific CD8+ cells by tetramer staining flow cytometry

The Use of Molecular Dynamics Simulation Method to Quantitatively Evaluate the Affinity between HBV Antigen T Cell Epitope Peptides and HLA-A Molecules

Improved preparation of class I HLA tetramers and their use in detecting CMV-specific CTL.

Cloning, expression, and purification of HLA-A2-BSP and β-2m in Escherichia coli

Cloning, expression, and purification of HLA-A2-BSP and beta-2m in Escherichia coli.

The characterization and structural basis of a human broadly binding antibody to HBV core protein

Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B

A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes

Establishment of hybridoma cell lines producing monoclonal antibodies against hepatitis B virus surface antigens (a, d, and r) and development of sensitive ELISA diagnostic test.

Complex Assembly, Crystallization And Preliminary X-Ray Crystallographic Studies Of Mhc H-2k(D) Complexed With An Hbv-Core Nonapeptide

Complex assembly, crystallization and preliminary X-ray crystallographic studies of MHC H-2Kd complexed with an HBV-core nonapeptide.

Preparation and identification of duck hepatitis B virus core protein monoclonal antibody

Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase